Sartorius Stedim Biotech S.A.
Sartorius Stedim Biotech S.A.
Your view on SDMHF
Overview
What the company does, where it operates, and who runs it.
About Sartorius Stedim Biotech S.A.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Rene Faber
- Headquarters
- Zone Industrielle Les Paluds, Aubagne, FR
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Rene Faber
- Headquarters
- Zone Industrielle Les Paluds, Aubagne, FR
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide.
The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products.
It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses.
In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France.
Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Sartorius Stedim Biotech S.A., and the rating behind it. SDMHF last traded at $217.53, 61.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Sartorius Stedim Biotech S.A.. Starting points for Sartorius Stedim Biotech S.A.: P/E 61.9, EPS $3.01, beta 1.25 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Sartorius Stedim Biotech S.A.. Sartorius Stedim Biotech S.A. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Sartorius Stedim Biotech S.A.. Trailing twelve-month EPS for Sartorius Stedim Biotech S.A. stands at $3.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Sartorius Stedim Biotech S.A.. Sartorius Stedim Biotech S.A. has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Sartorius Stedim Biotech S.A. valued side by side against its closest peers. Sartorius Stedim Biotech S.A. is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Sartorius Stedim Biotech S.A., and how their positions are changing. At a $21.16B market value, institutional positions materially move Sartorius Stedim Biotech S.A.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Sartorius Stedim Biotech S.A. executives and directors. Shares of Sartorius Stedim Biotech S.A. have traded between $170.00 and $264.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Sartorius Stedim Biotech S.A.. Sartorius Stedim Biotech S.A. is a $21.16B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Sartorius Stedim Biotech S.A.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Sartorius Stedim Biotech S.A.. Coverage tracks Sartorius Stedim Biotech S.A. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.